Julie D. Asch
Expertise in
5
conditions
Expertise in
5
conditions

Overview

Acute Leukemia and Lymphoma and blood and marrow/Stem cell transplant.Professional interests: Adolescent and Young Adults, Acute Lymphoblastic Leukemia. Personal interests: Skiing, biking, music.

Dr. Asch is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Asch is board certified in American Board Of Pediatrics, American Board Of Pathology , and American Board Of Pediatrics. She is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 4 clinical trials. Dr. Asch is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in UT

Board Certifications

American Board Of Pediatrics
American Board Of Pathology
American Board Of Pediatrics

Hospital Affiliations

Lds Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Blood & Marrow Transplant/Acute Leukemia Program
8th Ave & C St, Salt Lake City, UT 84143

Additional Areas of Focus

Dr. Asch has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


4 Clinical Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
View 2 Less Clinical Trial
Similar Doctors
Expertise in
6
conditions
Hematology | Oncology
Expertise in
6
conditions
Hematology | Oncology
Referral may be required

Pediatric Hematology-Oncology

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (2.2 miles away)
Languages Spoken:
English
Accepting New Patients

Elizabeth Raetz is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Raetz is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Raetz is board certified in American Board Of Pediatrics. Dr. Raetz is currently accepting new patients.

Expertise in
12
conditions
Hematology | Oncology
Expertise in
12
conditions
Hematology | Oncology
Referral may be required

University Of Utah Hospital Services

50 North Medical Drive, 
Salt Lake City, UT 
 (2.3 miles away)
Languages Spoken:
English, Japanese
Accepting New Patients

Dr. Pulsipher is currently the Division Chief of the Pediatric Hematology at Intermountain Primary Children's Hospital and Oncology, Director of the Children's and Adolescent Cancer Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah.  Dr. Pulsipher is an internationally recognized expert in Bone Marrow Transplantation and Cellular Therapy, having directed the world's largest pediatric transplant research group for more than a decade (Pediatric Transplantation and Cellular Therapy Consortium).  He has run more than 20 multicenter trials in the field and is considered and expert in broad areas of transplantation and cellular therapy.  Areas of focus have included development of reduced toxicity approaches to transplantation of both malignant and non-malignant disorders with a focus on minimizing short and long-term effects of transplant.  For non-malignant disorders he has run national protocols that have improved safety for patients with immunodeficiencies, HLH, and bone marrow failure. For cancer, he has developed techniques allowing identification of patients who can avoid radiation-based treatments for leukemia.  This has included a novel approach to safer transplantation of patients using half-matched family donors (haploidentical donors) using a novel form of bone marrow graft engineering called alpha-beta T-cell depletion.  His desire to develop safer approaches has become a major focus as he has led major studies in the field of chimeric antigen receptor T-cells (CAR T-cells), a safer approach to cancer cure.  Dr. Pulsipher's work in cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies. He has open protocols aimed at improving outcomes and his lab efforts are focused on making CAR T-cells that last longer and avoid overcome resistance by cancer cells. Dr. Pulsipher's interests have included ensuring that the families of those undergoing transplantation and cell therapy are psychologically well throughout the process.  To help with this, he has run several large trials assessing the safety and Quality of Life of pediatric bone marrow donors and is he currently running a large national trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652. For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830. Dr. Pulsipher is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Aplastic Anemia, and Bone Marrow Transplant. Dr. Pulsipher is board certified in American Board Of Pediatrics. Dr. Pulsipher is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Huntsman Cancer Institute, Univ. Of Utah

2000 Cir of Hope Dr, 
Salt Lake City, UT 
 (2.4 miles away)
Languages Spoken:
English
Accepting New Patients

Narendranath Epperla is a Hematologist practicing medicine in Salt Lake City, Utah. Dr. Epperla is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Epperla is board certified in American Board Of Internal Medicine. Dr. Epperla is currently accepting new patients.

Frequently Asked Questions about Dr. Julie D. Asch

How do I make an appointment with Dr. Julie D. Asch?

You can book an appointment with Dr. Julie D. Asch by calling their office at 801-408-1262. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julie D. Asch a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julie D. Asch is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julie D. Asch specialize in?

While Dr. Julie D. Asch is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Julie D. Asch participate in research or clinical trials?

Yes. Dr. Julie D. Asch has published 16 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Julie D. Asch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julie D. Asch accept my insurance?

Dr. Julie D. Asch accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 801-408-1262 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Asch's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile